Vitamin B6 (pyridoxine, pyridoxal, pyridoxamine, and their phosphate derivatives) is the cofactor that is required for the function of over 100 enzymes in the body and that is most critically involved in the transsulfuration pathway — the pathway by which the sulfur from methionine is transferred to cysteine and from cysteine to the other sulfur-containing compounds that are essential for human health. The two key enzymes of the transsulfuration pathway — cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CGL) — both require pyridoxal phosphate (PLP, the active coenzyme form of vitamin B6) as a cofactor, and without adequate PLP, the transsulfuration pathway cannot function, homocysteine accumulates, and the synthesis of cysteine, glutathione, taurine, and coenzyme A is impaired. This B6-dependent vulnerability of sulfur amino acid metabolism is one of the most important and least appreciated aspects of B6 nutrition, and it explains why B6 deficiency produces a similar metabolic phenotype to CBS deficiency — elevated homocysteine, reduced cysteine synthesis, and all of the clinical consequences that follow from the disruption of sulfur amino acid metabolism.
Cystathionine Beta-Synthase and the First Step of the Transsulfuration Pathway
Cystathionine beta-synthase (CBS) is the first and rate-limiting enzyme of the transsulfuration pathway — it condenses homocysteine with serine to form cystathionine, and it is allosterically activated by S-adenosylmethionine (SAM), the primary methyl donor in the body, which means that when SAM levels are high (as after a methionine-rich meal), CBS is activated and the transsulfuration pathway is engaged, converting the excess methionine sulfur to cysteine. CBS requires pyridoxal phosphate (PLP) as a cofactor — the aldehyde group of PLP forms a Schiff base with the epsilon-amino group of lysine in the CBS active site, and this PLP-dependent chemistry is essential for the condensation of homocysteine with serine. When B6 is deficient and PLP is not available, CBS activity falls, homocysteine accumulates, and the transsulfuration pathway is effectively shut down, even when the CBS enzyme itself is present and functional.
The clinical importance of PLP for CBS activity is underscored by the observation that B6 deficiency produces a similar elevation in homocysteine to that seen in CBS deficiency — in both cases, the transsulfuration pathway is impaired, homocysteine cannot be converted to cystathionine, and fasting homocysteine levels rise. The treatment of B6-responsive homocysteinuria (which is caused by CBS mutations that retain partial B6 responsiveness) with high-dose vitamin B6 (at 100-500mg daily of pyridoxine) is one of the most effective treatments in metabolic medicine — it lowers homocysteine levels in the majority of patients with B6-responsive CBS mutations and dramatically reduces the risk of the cardiovascular and thrombotic complications that are associated with elevated homocysteine.
Cystathionine Gamma-Lyase and the Final Step of the Transsulfuration Pathway
Cystathionine gamma-lyase (CGL) is the second enzyme of the transsulfuration pathway — it cleaves cystathionine to form cysteine, alpha-ketobutyrate, and ammonia, and it also requires PLP as a cofactor. Like CBS, CGL is a PLP-dependent enzyme, and when B6 is deficient, CGL activity falls and the conversion of cystathionine to cysteine is impaired. The clinical importance of CGL for cysteine synthesis is underscored by the observation that B6 deficiency reduces the synthesis of cysteine and of the downstream cysteine derivatives — including glutathione (the primary intracellular antioxidant), taurine (the second most abundant amino acid in the body, with critical roles in the heart, brain, and skeletal muscle), and coenzyme A (which is required for the function of the TCA cycle and for the metabolism of fatty acids). The broad range of cysteine-dependent metabolic pathways explains why B6 deficiency produces such a wide range of clinical manifestations — from the neurological effects of glutathione deficiency to the cardiovascular effects of homocysteine accumulation to the metabolic effects of impaired coenzyme A synthesis.
Practical Application
For general B6 supplementation, the evidence-based approach is to supplement with pyridoxal-5-phosphate (P5P, the active coenzyme form of B6) at 10-50mg daily, rather than with pyridoxine (the most common supplemental form, which must be converted to P5P in the liver before it can be used as a cofactor). P5P is preferred for people with the MTHFR C677T polymorphism (who may have impaired conversion of pyridoxine to P5P), for people with liver disease (who may have impaired conversion of pyridoxine to P5P), and for people who are taking medications that interfere with B6 metabolism. For comprehensive sulfur amino acid metabolism support, B6 pairs well with folate (which is required for the remethylation of homocysteine to methionine), with vitamin B12 (which is also required for the remethylation of homocysteine), with magnesium (which is a cofactor for many of the enzymes of sulfur metabolism), and with NAC (which provides a direct source of cysteine for glutathione synthesis and which bypasses the need for a functional transsulfuration pathway).
Leave a Reply